Randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: The REAL 2 trial
David Cunningham(Royal Marsden NHS Foundation Trust), A. R. Norman(Aberdeen Royal Infirmary), Gary Middleton(University of Birmingham), F. Daniel(Aberdeen Royal Infirmary), Timothy Iveson(University Hospital Southampton NHS Foundation Trust), Sujaya Rao(Aberdeen Royal Infirmary), J. Oates(Aberdeen Royal Infirmary), Fareeda Y. Coxon(Newcastle upon Tyne Hospitals NHS Foundation Trust), M. Nicolson, Naureen Starling(National Health Service)
Cited by 108
Related Papers
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k
Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection
|JAMA|2010|1.4k
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|1.3k
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study
|The Lancet Oncology|2019|1.2k
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
|New England Journal of Medicine|2018|1.1k